title: After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
authors.affiliation: Department of Anesthesiology, Division of Global Public Health, Department of Medicine, University of California, San Diego School of Medicine, San Diego, CA; Joint Masters Program in Health Policy and Law, University of California, San Diego School of Medicine and California Western School of Law, San Diego, CA; Global Health Policy Institute, La Jolla, CA. Electronic address: tmackey@ucsd.edu.
authors.forename: Tim K
authors.initials: TK
authors.lastname: Mackey
authors.affiliation: Global Health Policy Institute, La Jolla, CA.
authors.forename: Bryan A
authors.initials: BA
authors.lastname: Liang
mesh_terms: D000329:Advertising / Q000331:legislation & jurisprudence* / Q000592:standards; D004348:Drug Labeling / Q000331:legislation & jurisprudence* / Q000592:standards; D006293:Health Promotion / Q000331:legislation & jurisprudence*; D006801:Humans; D007880:Legislation, Drug; D056687:Off-Label Use / Q000331:legislation & jurisprudence* / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*